Home » Stocks » FHTX

Foghorn Therapeutics, Inc. (FHTX)

Stock Price: $19.52 USD 0.54 (2.85%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $20.94 +1.42 (7.28%) Jan 15, 6:37 PM
Market Cap 717.66M
Revenue (ttm) 179,000
Net Income (ttm) -58.06M
Shares Out 35.34M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $19.52
Previous Close $18.98
Change ($) 0.54
Change (%) 2.85%
Day's Open 18.81
Day's Range 18.54 - 20.05
Day's Volume 145,072
52-Week Range 15.12 - 25.88

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 months ago

US IPO market activity is picking back up ahead of the Thanksgiving holiday, with six IPOs scheduled to raise $3.4 billion in the week ahead. Biotech research product provider Maravai LifeScie...

Other stocks mentioned: GHLD, MCFE, MSP, NARI, SLQT
GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetical...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetical...

Seeking Alpha - 2 months ago

Foghorn Therapeutics Files Terms For $120 Million IPO

Market Watch - 2 months ago

Foghorn Therapeutics Inc. set terms for its initial public offering Monday, as the Massachusetts-based company focused on the chromatin regulatory system that leads to gene expression looks to...

About FHTX

Foghorn Therapeutics, a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The com... [Read more...]

Industry
Biotechnology
IPO Date
Oct 23, 2020
CEO
Adrian Gottschalk
Employees
85
Stock Exchange
NASDAQ
Ticker Symbol
FHTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is 25.00, which is an increase of 28.07% from the latest price.

Price Target
$25.00
(28.07% upside)
Analyst Consensus: Buy